You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

Dow
AstraZeneca
Medtronic
Moodys
Baxter
Johnson and Johnson

Last Updated: April 10, 2020

DrugPatentWatch Database Preview

TRANDOLAPRIL Drug Profile


Email this page to a colleague

» See Plans and Pricing

« Back to Dashboard

Which patents cover Trandolapril, and when can generic versions of Trandolapril launch?

Trandolapril is a drug marketed by Aurobindo Pharma, Cipla, Dr Reddys Labs Ltd, Epic Pharma, Epic Pharma Llc, Invagen Pharms, Lupin, Mylan, Teva Pharms, Watson Labs, and Glenmark Generics. and is included in eleven NDAs.

The generic ingredient in TRANDOLAPRIL is trandolapril; verapamil hydrochloride. There are ten drug master file entries for this compound. Three suppliers are listed for this compound. Additional details are available on the trandolapril; verapamil hydrochloride profile page.

Drug patent expirations by year for TRANDOLAPRIL
Drug Prices for TRANDOLAPRIL

See drug prices for TRANDOLAPRIL

Recent Clinical Trials for TRANDOLAPRIL

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
University of NebraskaPhase 4
Hospital Authority, Hong KongPhase 4
Assaf-Harofeh Medical CenterN/A

See all TRANDOLAPRIL clinical trials

Recent Litigation for TRANDOLAPRIL

Identify potential future generic entrants

District Court Litigation
Case NameDate
SANOFI-AVENTIS DEUTSCHLAND GMBH v. GLENMARK PHARMACEUTICALS INC., USA2007-12-07

See all TRANDOLAPRIL litigation

Pharmacology for TRANDOLAPRIL
Synonyms for TRANDOLAPRIL
(2S,3aR,7aS)-1-(((S)-1-ethoxy-1-oxo-4-phenylbutan-2-yl)-L-alanyl)octahydro-1H-indole-2-carboxylic acid
(2S,3aR,7aS)-1-((S)-N-((S)-1-Carboxy-3-phenylpropyl)alanyl)hexahydro-2-indolinecarboxylic acid, 1-ethyl ester
(2S,3aR,7aS)-1-(N-((1S)-1-((Ethyloxy)carbonyl)-3-phenylpropyl)-L-alanyl)octahydro-1H-indole-2-carboxylic Acid
(2s,3ar,7as)-1-[(2s)-2-[[(1S)-1-(ethoxycarbonyl)-3-phenylpropyl]amino]-1-oxopropyl]octahydro-1h-indole-2-carboxylic acid
(2S,3aR,7aS)-1-[(2S)-2-[[(2S)-1-ethoxy-1-oxidanylidene-4-phenyl-butan-2-yl]amino]propanoyl]-2,3,3a,4,5,6,7,7a-octahydroindole-2-carboxylic acid
(2S,3aR,7aS)-1-[(2S)-2-[[(2S)-1-ethoxy-1-oxo-4-phenylbutan-2-yl]amino]-1-oxopropyl]-2,3,3a,4,5,6,7,7a-octahydroindole-2-carboxylic acid
(2S,3aR,7aS)-1-[(2S)-2-[[(2S)-1-ethoxy-1-oxo-4-phenylbutan-2-yl]amino]propanoyl]-2,3,3a,4,5,6,7,7a-octahydroindole-2-carboxylic acid
(2S,3aR,7aS)-1-[(2S)-2-{[(2S)-1-ethoxy-1-oxo-4-phenylbutan-2-yl]amino}propanoyl]-octahydro-1H-indole-2-carboxylic acid
1-(2-((1-(ethoxycarbonyl)-3-phenylpropyl)amino)-1-oxopropyl)octahydro-1H-indol-2-carboxylic acid
1H-Indole-2-carboxylic acid, 1-((2S)-2-((1-(ethoxycarbonyl)-3-phenylpropyl)amino)-1-oxopropyl)octahydro-, (2S,3aR,7aS)-
1H-Indole-2-carboxylic acid, octahydro-1-(2-((1-(ethoxycarbonyl)-3-phenylpropyl)amino)-1-oxopropyl)-, (2S-(1(R*(R*)),2-alpha,3a-alpha,7a-beta))-
1T0N3G9CRC
679T376
87679-37-6
A842336
AKOS015843316
AKOS015896050
API0004465
AX8035229
BDBM50369775
BG0519
BIDD:GT0804
BRD-K28550399-001-01-4
C24H34N2O5
CAS-87679-37-6
CCG-222228
CCRIS 6594
CHEBI:9649
CHEMBL1519
CI-907
CS-2809
CTK8E8021
D00383
DB00519
DSSTox_CID_3692
DSSTox_GSID_23692
DSSTox_RID_77151
DTXSID2023692
FT-0082544
Gopten
GTPL6453
HMS3262J10
HY-B0592
KS-1467
LP00924
LS-82763
Mavik
Mavik (TN)
MFCD00865776
NCGC00095153-01
NCGC00182079-02
NCGC00182079-03
NCGC00261609-01
Odric
Odrik
Preran
Q929420
RU 44570
RU-44570
RU44570
s6468
SC-17973
SCHEMBL16610
SR-02000000917
SR-02000000917-2
ST24050183
TC-070968
Tox21_111453
Tox21_113152
Tox21_500924
Trandolapril (JAN/INN)
Trandolapril [INN:BAN]
Trandolapril [USP:INN:BAN]
Trandolapril, >=98% (HPLC), white powder
Trandolapril, European Pharmacopoeia (EP) Reference Standard
Trandolapril, United States Pharmacopeia (USP) Reference Standard
Trandolaprilum
Trandolaprilum [Latin]
Udrik
UNII-1T0N3G9CRC
VXFJYXUZANRPDJ-WTNASJBWSA-N
ZINC1853205
Paragraph IV (Patent) Challenges for TRANDOLAPRIL
Tradename Dosage Ingredient NDA Submissiondate
MAVIK TABLET;ORAL trandolapril 020528 2004-10-04

US Patents and Regulatory Information for TRANDOLAPRIL

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Glenmark Generics TRANDOLAPRIL AND VERAPAMIL HYDROCHLORIDE trandolapril; verapamil hydrochloride TABLET, EXTENDED RELEASE;ORAL 079135-001 May 26, 2010 AB RX No No   Start Trial   Start Trial   Start Trial
Watson Labs TRANDOLAPRIL trandolapril TABLET;ORAL 077805-001 Jun 12, 2007 DISCN No No   Start Trial   Start Trial   Start Trial
Glenmark Generics TRANDOLAPRIL AND VERAPAMIL HYDROCHLORIDE trandolapril; verapamil hydrochloride TABLET, EXTENDED RELEASE;ORAL 079135-002 May 26, 2010 AB RX No No   Start Trial   Start Trial   Start Trial
Watson Labs TRANDOLAPRIL trandolapril TABLET;ORAL 077805-002 Jun 12, 2007 DISCN No No   Start Trial   Start Trial   Start Trial
Aurobindo Pharma TRANDOLAPRIL trandolapril TABLET;ORAL 078438-001 Jun 12, 2007 AB RX No No   Start Trial   Start Trial   Start Trial
Invagen Pharms TRANDOLAPRIL trandolapril TABLET;ORAL 078320-003 Jun 12, 2007 DISCN No No   Start Trial   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Dow
AstraZeneca
Medtronic
Moodys
Baxter
Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.